The Lawsuit That Split Ibogaine Research in Two
Most people who research ibogaine today encounter two names early on: Howard Lotsof, the New York heroin user who stumbled onto ibogaine's effects in 1962, and Deborah Mash, the University of Miami neuropharmacologist whose clinical research in the 1990s shaped much of what came after. What far fewer people know is that these two collaborators ended up suing each other, in a dispute that split the early ibogaine research community and arguably slowed the field's progress toward FDA approval by years.
How the Partnership Started
In 1992, Lotsof, operating through his company NDA International, struck a research agreement with the University of Miami's School of Medicine to formally test ibogaine's safety and effects in humans. Deborah Mash, then an associate professor of neurology who had already built a reputation studying cocaine and alcohol toxicity, led the project. In August 1993, Mash and her colleagues appeared before the FDA's Drug Abuse Advisory Committee in Rockville, Maryland, requesting approval for the first clinical safety trial of high-dose ibogaine conducted in the United States. The hearing drew press coverage and demonstrators from the International Coalition of Addicts for Self-Help, who gathered outside pushing for approval. The committee's backing, and NIDA's parallel decision to sponsor animal studies into ibogaine beginning around 1991, gave the Lotsof-Mash collaboration real institutional legitimacy at a time when psychedelic research of any kind was still treated as reputationally risky for academic careers.
The Noribogaine Discovery That Changed Everything
During the research, Mash's lab identified noribogaine, a metabolite the human liver produces from ibogaine within hours of ingestion. She began to argue that noribogaine, not ibogaine itself, might be the compound actually responsible for ibogaine's long-term anti-addiction effects, since it remains active in the body well after ibogaine has been metabolized. This was a genuinely different scientific framework from Lotsof's original position, which held that ibogaine's visionary, hours-long psychoactive experience was central to how it interrupted addiction, not an incidental side effect of a more important downstream chemical.
According to accounts from that period, including one from Dana Beal, an ibogaine advocate and author of The Ibogaine Story, Mash and Lotsof initially agreed to split patent rights to the noribogaine discovery 50/50 between the University of Miami and NDA International. Mash has stated in interviews that Lotsof reneged on that handshake agreement almost immediately after returning to New York, instead demanding the patent be assigned to him alone, and separately filing for a related patent on something he called "noribogaine-plus," naming himself sole inventor.
The Lawsuit
In December 1996, Mash and the University of Miami filed a federal civil suit against Lotsof and NDA International. According to court filings from that period, the university alleged Lotsof had failed to complete a noribogaine patent application he was contractually obligated to file, and that he had improperly claimed credit for inventing noribogaine himself. Lotsof countersued, accusing the University of Miami of fraud and patent infringement, and pursuing what Beal characterized as an aggressive public campaign, including circulating allegations to the American Psychological Association, a body whose opinion mattered directly for Mash's academic grant reviews.
The dispute was never purely about money or credit. It reflected a genuine scientific disagreement about the mechanism behind ibogaine's effects, one that, as Beal put it at the time, could not simultaneously be true in both directions: either ibogaine's visionary experience and NMDA receptor activity mattered, or noribogaine alone, acting more like a long-acting opioid-blocking agent, was what counted. The field could not easily resolve that question while its two most prominent researchers were suing each other instead of collaborating.
What the Split Cost the Field
The practical fallout extended beyond the courtroom. Separately, a 1993 ibogaine-related death of a young woman in the Netherlands, which predated the lawsuit, had already created legal exposure for Lotsof and added pressure to an already strained research environment. NIDA's own Medications Development Division ultimately declined to pursue a large-scale ibogaine clinical program; the agency's advisors cited unresolved safety concerns from both the rat studies showing cerebellar cell damage at high doses and the two ibogaine-associated deaths on record by the mid-1990s, alongside doubts that existing human evidence, still largely anecdotal, justified the cost of a major trial. Whether a unified, well-funded Lotsof-Mash partnership could have changed that calculus is unknowable, but a fractured research community with competing patent claims certainly did not help the case.
Mash continued her ibogaine and noribogaine work independently after the split, eventually founding DemeRx to pursue noribogaine as a drug candidate in its own right. Lotsof continued advocating for ibogaine itself until his death in 2010, having secured a total of several U.S. patents for ibogaine-based addiction treatments across his lifetime, the first issued in 1985 and the last in 1992, shortly before the NDA-University of Miami agreement began.
Why This History Still Matters
The ibogaine-versus-noribogaine question Mash and Lotsof fought over in the 1990s has not disappeared. It persists today in ongoing research into noribogaine as a metabolite and in newer synthetic analogs designed around one mechanism or the other. Understanding that this scientific disagreement has a contentious, decades-old legal history helps explain why the field sometimes talks past itself, with some researchers and clinics emphasizing the psychoactive ibogaine experience as therapeutically essential, and others pursuing noribogaine-based or non-hallucinogenic alternatives as the more commercially and clinically viable path forward.
Practical Takeaway
If you are researching treatment options or following ibogaine news, it helps to know which camp a given source or clinic implicitly belongs to. A provider emphasizing the visionary experience as central to healing is operating in the Lotsof tradition. Research coverage focused on noribogaine, oxa-noribogaine, or related non-hallucinogenic derivatives traces more directly to the scientific direction Mash's lab took after 1996. Neither position is simply right or wrong, but conflating them, or assuming the field speaks with one voice, misses a genuine and unresolved scientific debate with real history behind it.